REGENERON PHARMACEUTICALS, INC.

REGN · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $80.7B · 15,410 employees
139
SEC Filings
$600.66
Close 2026-06-01
12
Transcripts
15,410
Employees

Business Summary

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. Its marketed products include EYLEA HD and EYLEA (aflibercept) for eye diseases, Dupixent (dupilumab) for allergic and inflammatory diseases, Libtayo (cemiplimab) for cancers, Praluent (alirocumab) for cardiovascular risk, Kevzara (sarilumab) for rheumatoid arthritis, and others. The company reported revenues of $14.3 billion in 2024.

Latest Stock Quote

REGN 2026-06-01 $600.66 O:$607.54 H:$614 L:$598.795 Vol:1.1M VWAP:$603.0291
origin leaf: bef5428a28e2cecdde550dc9c4a7da19b95002ac0bc4c177e0c701cc608d1c5a

Next Earnings

Q2 FY2026 — expected 2026-07-23

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionREGNdiscussed Blockchain & Crypto
topic_mentionREGNdiscussed Networking
topic_mentionREGNdiscussed Regulation
topic_mentionREGNdiscussed Automotive
topic_mentionREGNdiscussed Healthcare & Bio
topic_mentionREGNdiscussed Platform & Ecosystem
guidanceREGNguided expect a continuation of this trend with reimbursements from manufacturing of commercial supplies expected to be sequentially lower by approximately $40 million
guidanceREGNguided expect continued improvements in profitability from the Sanofi collaboration, which will continue to accelerate the paydown of the antibody development balance,
outlookREGNstated we anticipate will drive additional uptake
outlookREGNstated we expect significant category and competiti ve pressures that negatively impact U
company_mentionREGNmentioned AMD
topic_mentionREGNdiscussed Blockchain & Crypto
topic_mentionREGNdiscussed Networking
topic_mentionREGNdiscussed Supply Chain
topic_mentionREGNdiscussed Regulation
topic_mentionREGNdiscussed Gaming
topic_mentionREGNdiscussed Automotive
topic_mentionREGNdiscussed Healthcare & Bio
topic_mentionREGNdiscussed AI Compute
topic_mentionREGNdiscussed Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-042025-12-310000872589-26-000008EDGAR93K words
2025-02-052024-12-310001804220-25-000011EDGAR—
2024-02-052023-12-310001804220-24-000009EDGAR—
2023-02-062022-12-310001804220-23-000008EDGAR—
2022-02-072021-12-310001804220-22-000007EDGAR—
2021-02-082020-12-310001804220-21-000008EDGAR—
2020-02-072019-12-310001532176-20-000008EDGAR—
2019-02-072018-12-310001532176-19-000009EDGAR—
2018-02-082017-12-310001532176-18-000013EDGAR—
2017-02-092016-12-310001532176-17-000008EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-04-292026-03-310000872589-26-000016EDGAR—
2025-10-282025-09-300000872589-25-000028EDGAR58K words
2025-08-012025-06-300000872589-25-000019EDGAR—
2025-04-292025-03-310001804220-25-000022EDGAR—
2024-10-312024-09-300001804220-24-000040EDGAR—
2024-08-012024-06-300001804220-24-000028EDGAR—
2024-05-022024-03-310001804220-24-000017EDGAR—
2023-11-022023-09-300001804220-23-000031EDGAR—
2023-08-032023-06-300001804220-23-000023EDGAR—
2023-05-042023-03-310001804220-23-000016EDGAR—
2022-11-032022-09-300001804220-22-000031EDGAR—
2022-08-032022-06-300001804220-22-000023EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-290000872589-26-000014EDGAR—
2026-04-080001104659-26-040661EDGAR1K words
2026-01-300000872589-26-000004EDGAR10K words
2026-01-120001104659-26-002691EDGAR—
2025-10-280000872589-25-000026EDGAR—
2025-10-060001104659-25-096921EDGAR—
2025-08-010000872589-25-000017EDGAR—
2025-06-180001104659-25-060637EDGAR—
2025-04-290001804220-25-000020EDGAR—
2025-02-040001804220-25-000007EDGAR—

139 total filings indexed. 107 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Earnings Transcripts

Call DateQuarterTitle
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript
— REGN Earnings Call Transcript

Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

eye-diseases allergic-and-inflammatory-diseases cancer-/-oncology cardiovascular-and-metabolic-diseases neurological-diseases hematologic-conditions infectious-diseases rare-diseases velocimmune velocigene velocimab velocisuite velocimouse veloci-bi velocit velocihum altibodies

Company Identity

CIK0000872589
TickerREGN
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedNY
Websitehttps://www.regeneron.com
Listed1991-04-02

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 4c25d094df04274c5c7f4f037a306fdeb0147b71dc53aef9c83db3fc22e4750e
parent: 67d326e8a48560344dcf19cda25d46bd5d54c5a9409ad08a371e2ecaad0351e8
content hash: 6f696fb2131d310b04210dce41c4870378e1f7e63b85c75ce7513b4e28305018
signed: 2026-06-03T12:02:24.210Z
sources: 35 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf